This trial is studying how well binimetinib and imatinib work in treating patients with stage III-IV KIT-mutant melanoma that cannot be removed by surgery.
- Melanoma Stage III
- Metastatic Melanoma
1 Primary · 5 Secondary · Reporting Duration: Up to 2 years
Side Effects for
Awards & Highlights
1 Treatment Group
Treatment (binimetinib, imatinib)
1 of 1
25 Total Participants · 1 Treatment Group
Primary Treatment: Binimetinib · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What are the potential risks of Binimetinib to patients?
"The safety rating of Binimetinib is a 2, as there has been some evidence to support its safety profile but no data demonstrating efficacy in clinical trials." - Anonymous Online Contributor
Is this research endeavor actively enlisting participants?
"The current status of the medical trial, as per clinicaltrials.gov, is actively recruiting patients. It was first listed on March 3rd 2021 and recently updated on December 3rd 2021." - Anonymous Online Contributor
Have any other investigations utilized Binimetinib?
"Currently, there are 110 studies regarding binimetinib in progress with 18 of those trials having progressed to phase 3. While Cambridge England hosts several of these investigations, clinical trails related to Binimetinib can be found at 4,872 distinct sites worldwide." - Anonymous Online Contributor
What conditions can Binimetinib provide relief for?
"Binimetinib is primarily employed to treat newly diagnosed acute lymphoblastic leukaemia. Other conditions that may benefit from this pharmaceutical include unresectable melanoma, refractory ALL, and muscular dystrophy." - Anonymous Online Contributor
What is the aggregate size of this research cohort?
"Correct. Clinicaltrials.gov verifies that this research project, initially posted on March 3rd 2021, is now actively accepting participants. 25 volunteers are sought from a single medical site." - Anonymous Online Contributor